Actively Recruiting

Phase 2
Phase 3
Age: 40Years - 75Years
All Genders
NCT05020028

Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis

Led by NYU Langone Health · Updated on 2025-08-01

100

Participants Needed

1

Research Sites

218 weeks

Total Duration

On this page

Sponsors

N

NYU Langone Health

Lead Sponsor

O

Orcosa Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to see if cannabidiol (CBD) orally dissolving tablets (ODTs) can lessen pain, improve function, and improve patient satisfaction in cases of knee osteoarthritis. CBD comes from the cannabis plant and is non-psychoactive (i.e. does not produce a 'high' or altered mental state) as compared to tetrahydrocannabinol (THC), another compound found in cannabis. Researchers are studying different forms of CBD for potential use in treating pain, inflammation, and illnesses.

CONDITIONS

Official Title

Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis

Who Can Participate

Age: 40Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients presenting with knee osteoarthritis (KL Grade II-III)
  • Knee pain for at least three months, occurring in at least half of the days in that period
  • VAS 64; 4
  • Patients ages 40-75, inclusive
  • If female patients are pre-menopausal they must be currently practicing effective forms of two types of birth control, which are defined as those, alone or in combination, that result in a low failure rate (less than 1% per year) when used consistently and correctly
  • Male patients must be using an effective form of contraception
Not Eligible

You will not qualify if you...

  • Knee injections within the last 3 months (cortisone, PRP, hyaluronic acid)
  • Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)
  • Younger than 40 years of age
  • Older than 75 years of age
  • Any patient considered a vulnerable subject: pregnant women or fetuses, children, cognitively impaired adults, prisoners
  • History of cannabis abuse or dependence
  • History of coagulation abnormalities and thromboembolic disease or current abnormal coagulation test values
  • History of stroke or acute coronary syndromes within 3 months
  • Abnormal coagulation profile
  • Renal failure (serum creatinine > 250 bcmol/L [2.83 mg/dL]) or liver cirrhosis
  • Patients that have been on opioid management for any reason just prior to the study
  • Patients with known inflammatory arthritis (such as rheumatoid arthritis, gout, pseudogout etc)
  • Patients with a large effusion
  • Patients with a BMI > 35
  • Patients meeting the DSM-V for major psychiatric illness, such as bipolar disorder
  • Patients diagnosed with major depression, psychosis, or substance abuse disorder
  • Patients with current or a history of suicidal ideation
  • Breastfeeding females
  • Abnormal LFTs
  • Patients with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain/head injury, or seizures
  • Patients with moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C).
  • Patients taking moderate or strong inhibitors of CYP3A4 and CYP2C19 concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians
  • Patients taking strong CYP3A4 and CYP2C19 inducers concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians
  • Patients taking substrates of UTG1A9, UTGB17, CYP2A1, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

NYU Langone Health

New York, New York, United States, 10016

Actively Recruiting

Loading map...

Research Team

M

Michael J Alaia, MD

CONTACT

E

Emma Trasatti

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here